Home of Hepatology7 rue Daubin1203 GenevaSwitzerland+41 22 807 03 60easloffice@easloffice.eu© 2025 EASL. All rights reserved.Website by Soto.Privacy Policy | Cookie Policy | Terms & Conditions | Cyber Security Explore offerUnlock the full potential of being part of the EASLcommunity. As a member, you’ll gain access toexclusive resources, reduced event fees, top-tierjournals, and professional development opportunitiesdesigned to support your career in hepatologyBecome a memberNurses & Allied Health ProfessionalsLink titleYoung InvestigatorsLink titleBasic ScienceLink titleTitle here Lorem ipsum At the heart of EASL is a diverse and dynamic international community of professionals dedicated to advancing hepatology.Discover how you can get involved and make an impact.Whether you're a member, a Young Investigator, a nurse or allied health professional, or focused on basic science, there's a place for you here. Explore the different pathways to connect, grow and contribute, from membership benefits to tailored programmes and scientific networksLorem ipsum dolor sit ipsum CommunitySign In / Sign UpResourcesWhat We DoAbout Us Partnerships

Author name: EASL

EASL News

Interview with Sarina Shabso, 2024 Daniel Alagille Awardee

The recipient of the 2024 Daniel Alagille Award, Sarina Shabso, discusses her inspiring journey into the field of hepatology. Shabso’s path, from her early focus on skin regeneration to her groundbreaking research on genetic cholestatic diseases, showcases her dedication and innovative spirit, wh…

EASL News

Interview with Scott Waddell, 2023 Daniel Alagille Awardee

In an insightful conversation with EASL, Scott Waddell, the recipient of the 2023 Daniel Alagille Award, shares his journey into the field of hepatology. From his initial focus on cholangiocarcinoma to his pioneering work on polycystic liver disease, Waddell’s dedication and innovative approach h…

EASL News

European Medicines Association (EMA) statement on Obeticholic acid for the treatment of primary biliary cholangitis (PBC) European Association for the Study of the Liver (EASL) perspective

The EMA human medicines committee (CHMP) has recently issued a statement on Obeticholic acid for the treatment of Primary Biliary Cholangitis (PBC). The CHMP recommended to the European Commission that the market authorisation for Obeticholic acid in the European Union (EU) be revoked (https://ww…

EASL News

EASL announces JHEP Reports’ Impact Factor of 9.5 for 2023

The European Association for the Study of the Liver (EASL)is delighted to announce that JHEP Reports, its Open Access publication, achieved an impressive impact factor of 9.5 in the 2024 release of Journal Citation Reports (JCR) by Clarivate. This notable accomplishment underscores the journal’s …

EASL News

Launching the EASL Guidelines App!

Introducing the EASL Guidelines App – your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Developed by EASL, the European Association for the Study of the Liver, this app is meticulously designed to support healthcare professi…

EASL Congress

THRIVE related activities at EASL Congress 2024

THRIVE is an EU-founded initiative that brings together a strong and multidisciplinary team with 13 partners, from 8 countries, with complementary expertise in liver cancer research and in the use of cutting-edge technologies. The overall aim of the THRIVE project is to improve the outcome of bot…

Scroll to Top

Search EASL